Status:
ACTIVE_NOT_RECRUITING
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Crohn's Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline
- Confirmed diagnosis of moderate to severe CD as assessed by Crohn'
Exclusion
Key Trial Info
Start Date :
July 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 5 2029
Estimated Enrollment :
703 Patients enrolled
Trial Details
Trial ID
NCT05242471
Start Date
July 22 2022
End Date
November 5 2029
Last Update
December 19 2025
Active Locations (455)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama Liver Center
Birmingham, Alabama, United States, 35233
2
Del Sol Research Management, LLC
Tucson, Arizona, United States, 85715
3
Moore Clinical Trials, LLC
Little Rock, Arkansas, United States, 72205
4
Om Research LLC
Apple Valley, California, United States, 92307